Results
1 -
10 of
81
(Click
here to explore results)
- Beyond darunavir: recent development of next generation HIV-1 protease inhibitors to combat drug resistance. Arun K. Ghosh, Irene T. Weber, Hiroaki Mitsuya
, Chem. Commun.
, 2022
, 58
, 11762
- Stability-indicating thin-layer chromatographic method for determination of darunavir in complex darunavir–β-cyclodextrin in the presence of its degradation products. Ana Carolina Kogawa, Jaqueline Nakau Mendonça, Norberto Peporine Lopes, Hérida Regina Nunes Salgado
, Anal. Methods
, 2014
, 6
, 3689
- Anti-HIV drug repurposing against SARS-CoV-2. Peng Sang, Shu-Hui Tian, Zhao-Hui Meng, Li-Quan Yang
, RSC Adv.
, 2020
, 10
, 15775
- Biocatalytic routes to anti-viral agents and their synthetic intermediates. Sjoerd Slagman, Wolf-Dieter Fessner
, Chem. Soc. Rev.
, 2021
, 50
, 1968
- Joint neutron/molecular dynamics vibrational spectroscopy reveals softening of HIV-1 protease upon binding of a tight inhibitor. Daniel W. Kneller, Oksana Gerlits, Luke L. Daemen, Anna Pavlova, James C. Gumbart, Yongqiang Cheng, Andrey Kovalevsky
, Phys. Chem. Chem. Phys.
, 2022
, 24
, 3586
- Spontaneous single-crystal to single-crystal transition with self-healing cracks involving solvent exchange. Jie Shen, Hongzhen Bai, Xinbo Zhou, Jiyong Liu, Xiurong Hu, Paul K. Chu, Guping Tang
, CrystEngComm
, 2019
, 21
, 1102
- Micro-total process system machine (μ-TPSM) for rapid synthesis of antiretroviral darunavir. Ruchi Chauhan, Abhilash Rana, Subhash Ghosh, P. Srihari, Ajay K. Singh
, React. Chem. Eng.
, 2023
, 8
, 908
- Molecular docking reveals the potential of Salvadora persica flavonoids to inhibit COVID-19 virus main protease. Asmaa I. Owis, Marwa S. El-Hawary, Dalia El Amir, Omar M. Aly, Usama Ramadan Abdelmohsen, Mohamed S. Kamel
, RSC Adv.
, 2020
, 10
, 19570
- Mechanism of darunavir binding to monomeric HIV-1 protease: a step forward in the rational design of dimerization inhibitors. Mohd Ahsan, Chinmai Pindi, Sanjib Senapati
, Phys. Chem. Chem. Phys.
, 2022
, 24
, 7107
- Immune response and possible therapeutics in COVID-19. Anindya Dutta, Ananya Roy, Laboni Roy, Samit Chattopadhyay, Subhrangsu Chatterjee
, RSC Adv.
, 2021
, 11
, 960